Journal of the American Association of Nurse Practitioners 2015-08-01

Practical guidance on the recognition of uncontrolled asthma and its management.

Haley M Hoy, Louise C O'Keefe

Index: J Am Assoc Nurse Pract 27 , 466-75, (2015)

Full Text: HTML

Abstract

To highlight the significance of asthma in primary care and offer a practitioner-friendly interpretation of the asthma guidelines for the busy provider, while introducing new treatment options currently in clinical trials, such as the once-daily long-acting anticholinergic bronchodilator tiotropium Respimat.Articles with relevant adult data published between 2004 and 2015 were identified via PubMed. Additional references were obtained by reviewing bibliographies from selected articles.In the United States, uncontrolled or symptomatic asthma is common, with rates of 46%-78% in primary care. Uncontrolled asthma has a substantial impact on patients' quality of life and represents a significant healthcare burden. Nurse practitioners can improve patients' asthma control through education, monitoring, assessment, and treatment. Although asthma management guidelines are readily available, the authors recognize that nurse practitioners see patients with multiple comorbidities, all of which have treatment guidelines of their own.Nurse practitioners have a compelling opportunity as frontline caregivers and patient educators to recognize and assess uncontrolled asthma, along with determining the steps necessary to help patients gain and maintain symptom control.©2015 American Association of Nurse Practitioners.


Related Compounds

  • Roflumilast
  • Mometasone furoate

Related Articles:

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

2011-01-01

[BMC Clin. Pharmacol. 11 , 7, (2011)]

β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.

2011-01-01

[PLoS ONE 6 , e20000, (2011)]

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

2015-03-07

[Lancet 385(9971) , 857-66, (2015)]

Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

2013-01-01

[PLoS ONE 8 , e74640, (2013)]

Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.

2014-08-01

[Pulm. Pharmacol. Ther. 28(2) , 138-48, (2014)]

More Articles...